Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571011 | 0.83 | CCR2 (0.50) | CCR2 | |
| SCHEMBL8985586 | 0.82 | CCR2 (0.73) | CCR2 | |
| SCHEMBL1571399 | 0.82 | CCR2 (0.73) | CCR2 | |
| SCHEMBL1570490 | 0.81 | CCR2 (0.50) | CCR2 | |
| SCHEMBL5328493 | 0.80 | CCR2 (0.54) | CCR2 | |
| SCHEMBL1570793 | 0.79 | CCR2 (0.50) | CCR2 | |
| SCHEMBL5359183 | 0.78 | CCR2 (0.51) | CCR2 | |
| SCHEMBL1570771 | 0.78 | CCR2 (0.48) | CCR2 | |
| SCHEMBL8985396 | 0.77 | CCR2 (0.67) | CCR2 | |
| SCHEMBL1570788 | 0.76 | CCR2 (0.44) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307363-B1 | PIPERIDYL ACRYLAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-15 | — | — | EP | disclosed |
| US-8188287-B2 | Piperidyl acrylamide antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-29 | — | — | US | disclosed |
| EP-2307363-A1 | PIPERIDYL ACRYLAMIDE ANTOGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010008761-A1 | PIPERIDYL ACRYLAMIDE ANTOGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | WO | disclosed |
| US-20090318498-A1 | PIPERIDYL ACRYLAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318498-A1 | PIPERIDYL ACRYLAMIDE ANTAGONISTS OF CCR2 | CCR2, CX3CR1, CCR1 | CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.